1.Synchronous and metachronous malignancy in endometrial cancer patients treated in a tertiary care center of Thailand.
Siriwan TANGJITGAMOL ; Jakkapan KHUNNARONG ; Sunamchok SRIJAIPRACHAROEN
Journal of Gynecologic Oncology 2015;26(4):293-302
OBJECTIVE: To evaluate the prevalence and features of non-endometrial cancers in Thai endometrial cancer (EC) patients. METHODS: EC patients treated in our institution were identified and the following data were collected: age, EC stage, histopathology, adjuvant therapy, other cancers, living status, and cause of death. RESULTS: The mean age of the 344 patients was 56.8+/-10.8 years. Fifty (14.5%) had other synchronous and metachronous cancers. Mean ages of the patients with or without other cancers were not significantly different, 55.7+/-10.04 years versus 57.1+/-11.0 years, respectively (p=0.358). History of any cancer in the family and tumor in the lower uterine segment were more frequent among the patients with other cancers (6.0% vs. 1.7%, p=0.095; 12.0% vs. 1.0%, p<0.001; respectively). Six patients had > or =2 other cancers. Ovarian, breast, and colon were the three most common other cancers. After a median follow-up of 57.1 months, 18.3% of patients had died: 30.0% of patients with other cancers and 16.3% of those without other cancers. The corresponding EC deaths were 14.0% and 11.2%. The 5-year overall survival was significantly lower in patients who had other cancers: 79.3% (95% confidence interval [CI], 68.3 to 90.3) vs. 86.0% (95% CI, 81.7 to 90.3) than in those without (p=0.023). However, the corresponding disease-specific survival was not significantly different: 85.1% (95% CI, 75.5 to 94.7) compared with 89.0% (95% CI, 85.1 to 92.9), respectively (p=0.514). CONCLUSION: Thai EC patients had a high incidence of other cancers. Overall survival of EC patients who had other cancers was worse than those without, while disease-specific survival was not significantly different.
Breast Neoplasms/mortality/pathology/therapy
;
Chemotherapy, Adjuvant/methods
;
Colonic Neoplasms/mortality/pathology/therapy
;
Disease-Free Survival
;
Endometrial Neoplasms/mortality/*pathology/therapy
;
Female
;
Humans
;
Kaplan-Meier Estimate
;
Middle Aged
;
Neoplasm Recurrence, Local/mortality
;
Neoplasms, Multiple Primary/mortality/*pathology/therapy
;
Neoplasms, Second Primary/mortality/*pathology/therapy
;
Radiotherapy, Adjuvant/methods
;
Tertiary Care Centers/statistics & numerical data
;
Thailand/epidemiology
2.En bloc Resection for Right Colon Cancer Directly Invading Duodenum or Pancreatic Head.
Won Suk LEE ; Woo Yong LEE ; Ho Kyung CHUN ; Seong Ho CHOI
Yonsei Medical Journal 2009;50(6):803-806
PURPOSE: We undertook this study to analyze clinical features and surgical outcome of en bloc resections of the right side colon cancer directly invading duodenum and/or pancreatic head. MATERIALS AND METHODS: The records of all patients who underwent en bloc resection of duodenum and/or pancreas for right colon cancers were analyzed retrospectively. From September 1994 to September 2006, 1,016 patients underwent curative right hemicolectomy. Nine patients (0.9%) had en bloc resection of a right side colon cancer with duodenum or pancreatic head invasion. RESULTS: The median operative time was 320 minutes (range, 200-420) and the median blood loss was 700 mL (range, 100-2,000). The mean size of tumor was 6.6 cm (range, 3.2-10.7). The mean preoperative carcinoembryonic antigen (CEA) was 10.6 ng/mL (range, 0.2-50.8). There was no 30 day perioperative mortality. The median disease-free survival was 23.5 months [95% confidence interval (CI) 5.2-41.8] and the median overall survival was 28.1 months (95% CI 9.7-46.5). CONCLUSIONS: In patients with locally advanced right side colon cancer that directly invades the duodenum or pancreas can be safely resected with curative potential with minimum morbidity and mortality. Long term disease free survival can occur in a significant number of patients undergoing curative en bloc resection in this particular subset of patients.
Adult
;
Aged
;
Camptothecin/analogs & derivatives/pharmacology/therapeutic use
;
Chemotherapy, Adjuvant
;
Colonic Neoplasms/*complications/drug therapy/mortality/*surgery
;
Disease-Free Survival
;
Duodenal Neoplasms/drug therapy/mortality/*secondary/surgery
;
Duodenum/drug effects/*pathology/surgery
;
Female
;
Fluorouracil/pharmacology/therapeutic use
;
Humans
;
Leucovorin/pharmacology/therapeutic use
;
Male
;
Middle Aged
;
Organoplatinum Compounds/pharmacology/therapeutic use
;
Pancreas/drug effects/*pathology/surgery
;
Pancreatic Neoplasms/drug therapy/mortality/*secondary/surgery
;
Retrospective Studies
;
Treatment Outcome
3.Intravenous KITENIN shRNA Injection Suppresses Hepatic Metastasis and Recurrence of Colon Cancer in an Orthotopic Mouse Model.
Jun Eul HWANG ; Hyun Jeong SHIM ; Young Kyu PARK ; Sang Hee CHO ; Woo Kyun BAE ; Dae Eun KIM ; Kyung Keun KIM ; Ik Joo CHUNG
Journal of Korean Medical Science 2011;26(11):1439-1445
KITENIN (KAI1 C-terminal interacting tetraspanin) promotes invasion and metastasis in mouse colon cancer models. In the present study, we evaluated the effects of KITENIN knockdown by intravenous administration of short hairpin RNAs (shRNAs) in an orthotopic mouse colon cancer model, simulating a primary or adjuvant treatment setting. We established orthotopic models for colon cancer using BALB/c mice and firefly luciferase-expressing CT-26 (CT26/Fluc) cells. Tumor progression and response to therapy were monitored by bioluminescence imaging (BLI). In the primary therapy model, treatment with KITENIN shRNA substantially delayed tumor growth (P = 0.028) and reduced the incidence of hepatic metastasis (P = 0.046). In the adjuvant therapy model, KITENIN shRNA significantly reduced the extent of tumor recurrence (P = 0.044). Mice treated with KITENIN shRNA showed a better survival tendency than the control mice (P = 0.074). Our results suggest that shRNA targeting KITENIN has the potential to be an effective tool for the treatment of colon cancer in both adjuvant and metastatic setting.
Animals
;
Carrier Proteins/*genetics/metabolism
;
Cell Line, Tumor
;
Colonic Neoplasms/genetics/mortality/pathology/*therapy
;
Disease Progression
;
Liver Neoplasms/prevention & control/*secondary
;
Membrane Proteins/*genetics/metabolism
;
Mice
;
Mice, Inbred BALB C
;
Neoplasm Metastasis/*prevention & control
;
Neoplasm Recurrence, Local/genetics/*prevention & control
;
RNA Interference
;
RNA, Small Interfering/*therapeutic use
;
Tumor Markers, Biological/genetics